Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.5.1.59 - protein geranylgeranyltransferase type I

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Arthritis
Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice.
Arthritis, Rheumatoid
Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice.
Protein prenylation restrains innate immunity by inhibiting Rac1 effector interactions.
Targeting GGTase-I Activates RHOA, Increases Macrophage Reverse Cholesterol Transport, and Reduces Atherosclerosis in Mice.
Asthma
GGTI-2133, an inhibitor of geranylgeranyltransferase, inhibits infiltration of inflammatory cells into airways in mouse experimental asthma.
Upregulation of geranylgeranyltransferase I in bronchial smooth muscle of mouse experimental asthma: its inhibition by lovastatin.
Atherosclerosis
Discovery of geranylgeranyltransferase-I inhibitors with novel scaffolds by the means of quantitative structure-activity relationship modeling, virtual screening, and experimental validation.
Geranylgeranyl Transferase-I Knockout Inhibits Oxidative Injury of Vascular Smooth Muscle Cells and Attenuates Diabetes-Accelerated Atherosclerosis.
Targeting GGTase-I Activates RHOA, Increases Macrophage Reverse Cholesterol Transport, and Reduces Atherosclerosis in Mice.
Blindness
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Bone Diseases
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Bone Resorption
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Brain Neoplasms
Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
Breast Neoplasms
Blockade of protein geranylgeranylation inhibits Cdk2-dependent p27Kip1 phosphorylation on Thr187 and accumulates p27Kip1 in the nucleus: implications for breast cancer therapy.
Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence.
Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Gliotoxin is a dual inhibitor of farnesyltransferase and geranylgeranyltransferase I with antitumor activity against breast cancer in vivo.
Inhibition of transendothelial migration and invasion of human breast cancer cells by preventing geranylgeranylation of Rho.
PBK/TOPK mediates geranylgeranylation signaling for breast cancer cell proliferation.
Potentiation of Rho-A-mediated lysophosphatidic acid activity by hyperinsulinemia.
Candidiasis
Inhibiting Fungal Echinocandin Resistance by Small-Molecule Disruption of Geranylgeranyltransferase Type I Activity.
Carcinogenesis
Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity.
Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Structure of protein geranylgeranyltransferase-I from the human pathogen Candida albicans complexed with a lipid substrate.
Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.
Carcinoma
Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Involvement of RhoA and RalB in geranylgeranyltransferase I inhibitor-mediated inhibition of proliferation and migration of human oral squamous cell carcinoma cells.
Rapid induction of carcinomas and gamma-glutamyl transpeptidase-rich clones in N-methyl-N-benzylnitrosamine-treated hamster buccal pouch.
Carcinoma, Non-Small-Cell Lung
In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells.
Cardiovascular Diseases
Inhibition of geranylgeranyltransferase I decreases generation of vascular reactive oxygen species and increases vascular nitric oxide production.
Chagas Disease
Protein geranylgeranyltransferase-I of Trypanosoma cruzi.
Choroideremia
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Coinfection
Properties and kinetic mechanism of recombinant mammalian protein geranylgeranyltransferase type I.
Diabetic Retinopathy
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Glaucoma
Effects of pharmacologic inhibition of protein geranylgeranyltransferase type I on aqueous humor outflow through the trabecular meshwork.
Glioblastoma
Geranylgeranyltransferase I regulates HIF-1? promoting glioblastoma cell migration and invasion.
Glioma
Geranylgeranyltransferase I promotes human glioma cell growth through Rac1 membrane association and activation.
Geranylgeranyltransferase I regulates HIF-1? promoting glioblastoma cell migration and invasion.
Involvement of RalB in the effect of geranylgeranyltransferase I on glioma cell migration and invasion.
Glucose Intolerance
Inhibition of Mevalonate Pathway Prevents Adipocyte Browning in Mice and Men by Affecting Protein Prenylation.
Head and Neck Neoplasms
[Clinical values of serum PGGT (pancreas gamma-glutamyltranstidase and PGGT/TGGT ratio in diagnosis of cancer of the head of pancreas]
Hyperglycemia
Hyperinsulinemia enhances transcriptional activity of nuclear factor-kappaB induced by angiotensin II, hyperglycemia, and advanced glycosylation end products in vascular smooth muscle cells.
Hyperinsulinism
Garlic extract methylallyl thiosulfinate blocks insulin potentiation of platelet-derived growth factor-stimulated migration of vascular smooth muscle cells.
Hypersensitivity
Inhibiting Fungal Echinocandin Resistance by Small-Molecule Disruption of Geranylgeranyltransferase Type I Activity.
Infections
Differential requirements of protein geranylgeranylation for the virulence of human pathogenic fungi.
Inhibiting Fungal Echinocandin Resistance by Small-Molecule Disruption of Geranylgeranyltransferase Type I Activity.
Invasive Fungal Infections
Geranylgeranyltransferase I of Candida albicans: null mutants or enzyme inhibitors produce unexpected phenotypes.
Leber Congenital Amaurosis
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Liver Neoplasms
[Clinical values of serum PGGT (pancreas gamma-glutamyltranstidase and PGGT/TGGT ratio in diagnosis of cancer of the head of pancreas]
Lung Neoplasms
Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.
GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.
In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells.
Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.
Lymphoma
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
Lymphoma, B-Cell
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
Lymphoma, Large B-Cell, Diffuse
Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines.
Lymphoma, T-Cell
Roles of GTP and Rho GTPases in pancreatic islet beta cell function and dysfunction.
Lymphopenia
Mevalonate metabolism-dependent protein geranylgeranylation regulates thymocyte egress.
Malaria
Theoretical Studies on Binding and Specificity Mechanisms of Farnesyltransferase (FTase) and Geranylgeranyl transferase type-I (GGTase-I) Inhibitors by Molecular Modeling.
Multiple Myeloma
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.
Multiple Sclerosis
Discovery of geranylgeranyltransferase-I inhibitors with novel scaffolds by the means of quantitative structure-activity relationship modeling, virtual screening, and experimental validation.
Neoplasm Metastasis
Geranylgeranyltransferase I promotes human glioma cell growth through Rac1 membrane association and activation.
Molecular and Pharmacological Characterization of the Interaction between Human Geranylgeranyltransferase Type I and Ras-Related Protein Rap1B.
Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.
Neoplasms
A Zebrafish Chemical Suppressor Screening Identifies Small Molecule Inhibitors of the Wnt/?-catenin Pathway.
Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.
Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo.
Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: important mechanistic and bench to bedside issues.
Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter.
Farnesyltransferase and geranylgeranyltransferase I: structures, mechanism, inhibitors and molecular modeling.
Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem.
Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes.
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Geranylgeranyltransferase I as a target for anti-cancer drugs.
Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Geranylgeranyltransferase I Inhibitors Target RalB To Inhibit Anchorage-Dependent Growth and Induce Apoptosis and RalA To Inhibit Anchorage-Independent Growth.
Geranylgeranyltransferase I promotes human glioma cell growth through Rac1 membrane association and activation.
GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.
GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells.
Heterogeneity of hepatocyte antigen expression in rat liver carcinogenesis: concordance between neoplastic nodules and tumours.
In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I.
Inhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-I? Expression.
Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
Molecular and Pharmacological Characterization of the Interaction between Human Geranylgeranyltransferase Type I and Ras-Related Protein Rap1B.
Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells.
p21(WAF1/CIP1) is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor beta- and Sp1-responsive element: involvement of the small GTPase rhoA.
Protein Geranylgeranyltransferase Type 1 as a Target in Cancer.
Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.
Targeting the protein prenyltransferases efficiently reduces tumor development in mice with K-RAS-induced lung cancer.
The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity.
The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner.
The inhibitory effect of oral administration of garlic on experimental carcinogenesis in hamster buccal pouches by DMBA painting.
Theoretical Studies on Binding and Specificity Mechanisms of Farnesyltransferase (FTase) and Geranylgeranyl transferase type-I (GGTase-I) Inhibitors by Molecular Modeling.
[Clinical values of serum PGGT (pancreas gamma-glutamyltranstidase and PGGT/TGGT ratio in diagnosis of cancer of the head of pancreas]
Pancreatic Neoplasms
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancer.
In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I.
Papilloma
Rapid induction of carcinomas and gamma-glutamyl transpeptidase-rich clones in N-methyl-N-benzylnitrosamine-treated hamster buccal pouch.
Progeria
Genetic studies on the functional relevance of the protein prenyltransferases in skin keratinocytes.
Prostatic Neoplasms
Inhibition of GGTase I and FTase disrupts cytoskeletal organization of human PC-3 prostate cancer cells.
protein geranylgeranyltransferase type i deficiency
Geranylgeranyltransferase type I (GGTase-I) deficiency hyperactivates macrophages and induces erosive arthritis in mice.
GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.
Retinal Diseases
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Retinoblastoma
The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity.
Squamous Cell Carcinoma of Head and Neck
Involvement of RhoA and RalB in geranylgeranyltransferase I inhibitor-mediated inhibition of proliferation and migration of human oral squamous cell carcinoma cells.
Stomach Neoplasms
Geranylgeranylation promotes proliferation, migration and invasion of gastric cancer cells through the YAP signaling pathway.
Toxoplasmosis
Theoretical Studies on Binding and Specificity Mechanisms of Farnesyltransferase (FTase) and Geranylgeranyl transferase type-I (GGTase-I) Inhibitors by Molecular Modeling.
Vascular System Injuries
Inhibition of geranylgeranyltransferase I decreases generation of vascular reactive oxygen species and increases vascular nitric oxide production.